Skip to content

Effect of citalopram in schizophrenia

Effect of citalopram as an adjuvant with atypical antipsychotics on psychotic symptoms in chronic schizophrenia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180619040161N1
Enrollment
30
Registered
2018-09-20
Start date
2018-09-23
Completion date
Unknown
Last updated
2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: receive an Risperidone 8mg/day plus Citalopram 20mg/day for 8 weeks. Intervention 2: Control group: receive an Risperidone 8mg/day for 8 weeks.

Sponsors

Oroumia University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Diagnosis of Schizophrenia according to DSM5 criteria and clinical interview by psychiatrist Age range 15-65 years Ability to provide informed consent and cooperation with study procedures At least, 5 years history of schizophrenia Participants needed to be currently taking an Atypic antipsychotic agent for 6 month prior to study Based on the HAM-D scale, having a score of less than 20

Exclusion criteria

Exclusion criteria: Patients under treatment with clozapin Any sever mental disorder(major depressive disorder, psychotic symptoms, manic phase symptoms,…) Renal, hepatic, thyroid, or hematological disorder; and any sever and chronic medical disorder Pregnancy or lactation Individuals on antidepressants treatment for other indications (Tricyclic antidepressant , MAO inhibitor ,Selective serotonine reuptake inhibitor,… )for 1 month prior to randomization Prior history of convulsion , stroke and head trauma History of mental retardation (IQ less than 70) History of substance abuse or dependence within 6months prior to study participation (except nicotine or caffeine dependence)

Design outcomes

Primary

MeasureTime frame
Severity of positive and negative symptom of Schizophrenia. Timepoint: Before intervention (first visit) ,the end of the fourth week (second visit),the end of the eighth week (third visit). Method of measurement: At each visit to the SANS and SAPS testing will be completed.

Secondary

MeasureTime frame
Clinical Global Impression-Improvement. Timepoint: End of eight weeks. Method of measurement: CGI Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSafar Hamednia

Oroumia University of Medical Sciences

dr.hamednia@yahoo.com+98 44 3272 2932

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026